Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective destruction of pancreatic islet β-cells that produce insulin, in the context of an underlying multigenetic inheritance 1 . When most of the β-cells are destroyed or non-functional, the ensuing lack of insulin results in hyperglycemia and requires life-long insulin-replacement therapy 1 . The physiopathology of T1D involves inappropriate activation of both the innate immune system and adaptive immune system, which induces loss of self-tolerance and islet destruction 2-5 . T1D is characterized by the presence of anti-islet autoantibodies and autoreactive T cells. Innate immune cells are involved at various stages of the disease and are particularly important for the initiation of the local immune response in the pancreas and the pancreatic lymph nodes (PLNs) 2, 4 . Published data have highlighted the role of the intestinal microbiota in T1D by transfer experiments in mice of the non-obese diabetic (NOD) strain 6-8 and gut microbiota differences in children that are associated with the development of T1D 9-11 . Several studies have also described alterations to the gut mucosa in NOD mice and patients with T1D [12] [13] [14] [15] [16] .
Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective destruction of pancreatic islet β-cells that produce insulin, in the context of an underlying multigenetic inheritance 1 . When most of the β-cells are destroyed or non-functional, the ensuing lack of insulin results in hyperglycemia and requires life-long insulin-replacement therapy 1 . The physiopathology of T1D involves inappropriate activation of both the innate immune system and adaptive immune system, which induces loss of self-tolerance and islet destruction [2] [3] [4] [5] . T1D is characterized by the presence of anti-islet autoantibodies and autoreactive T cells. Innate immune cells are involved at various stages of the disease and are particularly important for the initiation of the local immune response in the pancreas and the pancreatic lymph nodes (PLNs) 2, 4 . Published data have highlighted the role of the intestinal microbiota in T1D by transfer experiments in mice of the non-obese diabetic (NOD) strain [6] [7] [8] and gut microbiota differences in children that are associated with the development of T1D [9] [10] [11] . Several studies have also described alterations to the gut mucosa in NOD mice and patients with T1D [12] [13] [14] [15] [16] .
Mucosal-associated invariant T cells (MAIT cells) are innate-like T cells that recognize bacterial metabolites derived from the synthesis of riboflavin and presented by the monomorphic major histocompatibility complex (MHC) class-I-related protein MR1 (refs. 17-19) . These non-conventional T cells express a conserved αβ T cell antigen receptor (TCR) that consists of an invariant TCR α-chain (α-chain variable region 7.2 and α-chain joining regions 33, 20 and12 (V α 7.2-J α 33, 20, 12) in humans and V α 19-J α 33 in mice) with a restricted set of TCR β-chains. MAIT cells produce various cytokines, such as TNF, IFN-γ, IL-17 and granzyme B (GzB), that participate in tissue inflammation and cell death 17, [20] [21] [22] [23] [24] [25] [26] [27] [28] . The nearly complete absence of MAIT cells in germ-free mice 17, 29 and their physiological localization at mucosal sites, including the gut 17, 21 , suggest a strong interaction with the microbiota. Here we found alterations in MAIT cells in patients with T1D and, through the use of NOD mice, revealed a protective role for MAIT cells directed against T1D. The localization and function of MAIT cells highlight their key role in the maintenance of gut integrity whereby they control the development of autoimmune responses to pancreatic β-cells.
RESULTS

Alterations in MAIT cells in children with recent-onset T1D
We first began our investigation of MAIT cells in T1D by analyzing the frequency and phenotype of MAIT cells in fresh peripheral A r t i c l e s blood samples from children with recent-onset T1D and children with established T1D, as well as age-matched control children (with disorders unrelated to diabetes) (Supplementary Tables 1 and 2). We identified MAIT cells in human blood as CD4 − T lymphocyte that expressed the V α 7.2 TCR α-chain segment and had high expression of the natural killer cell receptor CD161, according to published studies 18, 19, 22, 30 (Fig. 1a) . The frequency and number MAIT cells was threefold lower in the blood of children with recent-onset T1D than in that of control children, whereas no significant difference between children with established disease and control children was observed in these parameters ( Fig. 1a and Supplementary Fig. 1) . A lower frequency of both CD8 + MAIT cells and CD4 − CD8 − double negative (DN) MAIT cells was observed in the blood of children with recentonset T1D than in that of control children (Supplementary Fig. 1 ). There was no difference among the three populations of children in the frequency of conventional CD4 + or CD8 + T cells or that of V α 7.2 + CD161 − T cells (data not shown), which confirmed that the decrease in the frequency of MAIT cell at the onset of T1D was not secondary to changes in other T cell populations or to downregulation of CD161 expression. Analysis of the phenotype of MAIT cells showed a lower frequency of MAIT cells expressing tissue-recruitment and/or adhesion molecules (CCR6 and CD56) at the onset of the disease, relative to the frequency of such cells later in disease, as well as a higher frequency of MAIT cells expressing the activation and/or exhaustion markers CD25 and PD-1, and a lower frequency of MAIT cells expressing the anti-apoptotic molecule BCL-2 (Fig. 1b,c) . Multiparameter analysis of MAIT cells from the children with established T1D highlighted the intermediate phenotype of their MAIT cells, between that of such cells from children with recent-onset T1D and that of such cells from control children (Fig. 1c) . In children with recent-onset T1D, the frequency of MAIT cells expressing the migratory molecule CCR6 or the anti-apoptotic molecules BCL-2 was positively correlated with the overall frequency of MAIT cells, whereas the expression of CD25 by MAIT cell was negatively correlated with the overall frequency of MAIT cells (Supplementary Fig. 2 ). These data suggested that the decreased frequency of MAIT cells in blood might have reflected their migration to inflamed tissues and/or their death by apoptosis subsequent to their activation.
Alteration in blood-MAIT-cell function in children with T1D
The production of cytokines and GzB by fresh-blood MAIT cells was analyzed after stimulation of the cells with the phorbol ester PMA and ionomycin. MAIT cells from children with recent-onset T1D produced less IFN-γ than did MAIT cells from control children, whereas their production of TNF, IL-4 and GzB was higher than that of MAIT cells from control children (Fig. 2a,b) . Among those effector molecules, only the frequency of GzB-producing MAIT cells correlated with the overall frequency of MAIT cells: greater GzB production was observed in patients with a lower frequency of MAIT cells (data not shown). Multi-parameter analysis of the production of cytokines and GzB by MAIT cells also showed that blood MAIT cells from children with established T1D had an intermediate status between that of such cells from control children and such cells from children with recentonset T1D (Fig. 2b) , as already observed for the surface phenotype of MAIT cells (Fig. 1c) . We next analyzed the ability of MAIT cells to respond to specific activation of the TCR by the MAIT-cell ligand (and riboflavin derivative) 5-OP-RU 19 represents an individual subject; small horizontal lines indicate the median. *P < 0.05, **P < 0.01 and ***P < 0.001 (Kruskal-Wallis test followed by the Wilcoxon rank-sum test adjusted by the Holm method). Data are representative of 39 experiments.
A r t i c l e s CD69 and CD25 (Fig. 2c) . The addition of a blocking monoclonal antibody to MR1 confirmed that the activation was TCR dependent (Fig. 2c) . The activation MAIT cells from children with recent-onset T1D was significantly lower than in that of MAIT cells from control children (Fig. 2c) . Together these results highlighted functional alteration of MAIT cells in children with recent-onset T1D.
Cytotoxic effect of MAIT cells on human b-cells
We next investigated potential links between the phenotype of and functional alterations to MAIT cells and the clinical characteristics of children with recent-onset T1D (Supplementary Tables 1 and 2 ). The frequency of GzB + MAIT cells was negatively associated with the age of the children at diagnosis (Fig. 3a) , in agreement with the current view that T1D is more aggressive in the youngest children 31, 32 . Other parameters of MAIT cells, such as their frequency and their expression of CCR6 and BCL-2, were also associated with age at diagnosis (Supplementary Fig. 2 ). No substantial correlation between MAITcell parameters and age was observed for control children or children with established T1D (data not shown). The production of GzB by MAIT cells was inversely correlated with the concentration of glycated A r t i c l e s hemoglobin (HbA1c) in blood at the onset of disease, but this inverse correlation was not found in children with established T1D (Fig. 3a) . Indeed, a more-aggressive disease associated with sustained abnormalities in MAIT cells would suggest a shorter time of hyperglycemia before the onset and thus lower concentrations of HbA1c 32 . The strong inverse correlation between the production of GzB by MAIT cells and the age of the children at the time of disease onset suggested that MAIT cells might participate in β-cell death. Inflammatory cytokines usually produced in inflamed islets during the progression of T1D (IL-1β, IFN-γ and TNF) induced upregulation of MR1 expression on the human β-cell line EndoC-βH1 (Fig. 3b) . Moreover, co-culture experiments demonstrated direct killing of EndoC-βH1 cells 33 by purified MAIT cells from healthy donors (Fig. 3c,d) . MAIT cells induced MR1-dependent apoptosis of EndoC-βH1 cells (as defined by positive staining with annexin V and negative staining with propidium iodide) that was more efficient for Endo-βH1 cells pre-incubated with inflammatory cytokines (Fig. 3c,d) . During co-culture, MAIT cells were activated (as defined by upregulation of CD25 expression) and degranulated (as defined by expression of the lectin ligand CD107a) (Fig. 3e) . Together these data suggested that in the inflamed pancreas during diabetes progression, MAIT cells might participate in β-cell destruction.
MAIT-cell alterations at different disease stages
To further explore the link between MAIT-cell parameters and clinical characteristics, we analyzed 15 of the children with recent-onset T1D at 1 year after diagnosis (and the beginning of insulin treatment). Although the frequency of MAIT cells among T cells after 1 year of insulin treatment remained at a level similar to that before insulin treatment began, the frequency of both CCR6 + MAIT cells and BCL-2 + MAIT cells was significantly higher after 1 year of insulin treatment than before insulin treatment began (Fig. 4a) . Conversely, after 1 year A r t i c l e s of insulin treatment, the frequency of CD25 + , PD1 + , IL-17A + and, to some extent, GzB + MAIT cells in these children decreased to the frequency observed in the control children (Fig. 4a) . This longitudinal analysis strengthened the data obtained in the transversal analysis, showing that the phenotype of MAIT cells from children after insulin treatment was more similar to that of such cells from control children than to that of such cells from children at disease onset.
MAIT cells as a new biomarker of T1D
We performed canonical analysis to compare MAIT-cell alterations in the three groups of children above (control, recent-onset T1D and established T1D). This analysis revealed that MAIT-cell parameters were sufficient to distinguish among the three groups of children analyzed (Fig. 4b) . Moreover, statistical regression analysis identified four surface markers (CCR6, CD25, PD-1 and CD56) that defined a predictive model for diagnosis of the disease, as tested on a receiveroperating-characteristic curve (Fig. 4c) .
We confirmed in another cohort of children from Milan that alterations in the frequency and phenotype of MAIT cells were observed in children with recent-onset T1D, relative to that of age-matched control children (Supplementary Table 3 and Supplementary  Fig. 3 ). However, technical difficulties that affected the analysis of CD56 in frozen cells did not allow application of the predictive model to this cohort.
Finally, to investigate whether alterations in MAIT cells could be detected before the onset of diagnosis, we characterized MAIT cells in adults at risk of developing T1D, defined as direct relatives of patients with T1D, with at least two positive autoantibodies (Supplementary Table 4 ). There was a greater frequency of CD25 + and PD-1 + MAIT cells and a trend toward a lower frequency of CCR6 + MAIT cell in the at-risk subjects, relative to the frequency of such cells in the control group (healthy adults not at risk of developing T1D), even though the number of subjects analyzed was limited (Fig. 4d) . These patient data suggested that MAIT cells might be used as a biomarker in T1D and might have a role in the pathogenesis of T1D.
MAIT-cell characterization in NOD mice
The NOD mouse is the most-studied animal model of T1D because it shares many features with the human disease 3, 4 ; thus, we investigated whether any of the MAIT-cell alterations observed in patients with T1D were evident in this model. We characterized MAIT cells in 10-week-old NOD and C57BL/6 mice using mouse MR1 tetramers loaded with the riboflavin derivative 5-OP-RU and control tetramers loaded with the non-agonist folate derivative acetyl-6-FP (Ac-6-FP) 19, 25, 29, 34 (Fig. 5a) . The frequency and absolute number of MAIT cells was three-to tenfold lower in the spleen and PLNs of NOD mice than in those of C57BL/6 mice ( Fig. 5b) . However, MAIT cells were present in pancreatic islets of NOD mice and were more abundant in the ileum of NOD mice than in that of C57BL/6 mice ( Fig. 5b) . Of note, circulating MAIT cells were below the limit of detection in the blood of NOD mice (data not shown). Mouse MAIT cells can be categorized into three subsets: CD4 + cells, CD8 + cells or DN cells 34 . MAIT cells in peripheral tissues of C57BL/6 mice were mainly DN and expressed the activation and memory marker CD44 ( Fig. 5d and Supplementary Fig. 4 ) and thus corresponded to functionally mature MAIT cells 29 . In contrast, the proportion of DN MAIT cells was lower in NOD mice than in C57BL/6 mice (Fig. 5c,d) . Analysis of activation markers on MAIT cells from NOD mice revealed high expression of CD69 in pancreatic islets and ileum and elevated expression of CD25 in PLNs and islets, relative to such expression in the other tissues analyzed (Fig. 5e,f) . While CD69 expression was also higher on ileal MAIT cells from C57BL/6 mice than on those from NOD mice, CD25 expression was not upregulated in PLNs from C57BL/6 mice relative to its expression in PLNs from NOD mice (Fig. 5f) . Of note, CD44 was expressed on more ileal MAIT cells from NOD mice than from C57BL/6 mice ( Fig. 5f) . As for cytokine production in NOD mice, in all tissues assessed, MAIT cells produced IL-17A and TNF and, to a lesser extent, IFN-γ and IL-22 (Fig. 5g,h) . Moreover, the majority of MAIT cells in the PLNs and ileum of NOD mice expressed CD44 and produced large amounts of IL-17A and TNF (Fig. 5g,h) . Notably, similar production of the cytokines TNF, IFN-γ and IL-22 was observed C57BL/6 mice and NOD mice, except in islets (Fig. 5h) . Of note, a higher frequency of MAIT cells from NOD mice than from C57BL/6 A r t i c l e s mice produced IL-17 (Fig. 5h) ; this might contribute to inflammation and diabetes progression. As in C57BL/6 mice 30, 34, 35 , most MAIT cells in NOD mice expressed PLZF, RORγt and T-bet, transcription factors characteristic of this innate-like T cell lineage 21 ( Supplementary Fig.  5 ). Together these data showed that spleen MAIT cells were less frequent and less mature in NOD mice than in C57BL/6 mice; however, they had an activated phenotype and produced cytokines in the PLNs, islets and ileum of NOD mice.
MAIT cells during diabetes development in NOD mice
We next analyzed MAIT cells in NOD mice at three stages of disease development: early (6-7 weeks of age), pre-diabetic (15-17 weeks of age) and the onset of diabetes (Fig. 6a) . These three stages correspond to mild peri-insulitis characterized by moderate infiltration of inflammatory cells around pancreatic islets, to insulitis associated with partial β-cell destruction and to severe destructive insulitis that results in insufficient insulin production 4,5 and hyperglycemia, respectively.
During disease progression, the frequency of MAIT cells increased in pancreatic islets and, transiently, in the spleen and ileum (Fig. 6a) . These data showed that disease progression was associated with modification of the tissue distribution of MAIT cells. Since MAIT cells are effector cells and can migrate to inflamed tissues, we analyzed their migration by transfer experiments. We transferred MAIT cells (from NOD donor mice with transgenic expression of V α 19 and homozygous deficiency in the gene encoding the α-chain constant region (Trac −/− )) into congenic NOD mice at two stages of disease development. There was greater recruitment of MAIT cells into the pancreas of 20-to 25-week-old NOD mice than into that of younger (8-to 10-week-old) NOD mice (Fig. 6b) . In contrast, the recruitment of MAIT cells into the ileum decreased with aging ( Fig. 6b) , in support of the finding of a decreased frequency of MAIT cells in this tissue in diabetic NOD mice.
To further explore the function of MAIT cells in T1D, we analyzed their cytokine production in various tissues at the three stages of disease A r t i c l e s development noted above. For this purpose, we sorted MAIT cells by MR1 tetramer staining and analyzed Gzmb, Ifng, Il17a and Il22 mRNA in the sorted cells by RT-qPCR (Fig. 6c,d) . In pancreatic islets and ileum, the cytokine profiles of MAIT cells changed with disease progression. In islets, the production of IFN-γ by MAIT cells was detected in diabetic mice (onset of disease throughout), and GzB was already detectable at the pre-diabetic stage and further increased in diabetic mice (Fig. 6c) . Both GzB and IFN-γ from MAIT cells participate in pancreatic β-cell death 4 . This increased production of IFN-γ and GzB in islets was confirmed at the protein level (Fig. 6e) . In the ileum of NOD mice, the development of T1D was associated with decreased levels of Il17a and Il22 mRNA in MAIT cells at the diabetic stage (Fig. 6d) . Diminished production of IL-17A and IL-22 by ileal MAIT cells from diabetic NOD mice was confirmed by intracellular staining (Fig. 6f) . Together these results suggested that MAIT cells might have a dual role in NOD mice according to their tissue localization, promoting β-cell death in the pancreas but participating in homeostasis of the gut mucosa.
Gut-mucosa alterations during T1D progression in NOD mice
Since RORγt is an important transcription factor that controls IL-17A 36 and is involved in IL-22 production 37,38 , we analyzed RORγt expression in MAIT cells in the ileum of NOD mice expressing green fluorescent protein (GFP) as a reporter of RORγt expression (Fig. 7a) . According to the level of IL-17A and IL-22 in diabetic mice (Fig. 6e,f) , RORγt expression was also decreased at the onset of diabetes (Fig. 7a) . IL-23 is a key cytokine that induces IL-17 expression under the control of RORγt. The expression of Il23a transcripts was decreased in the ileum of mice at the onset of diabetes relative to their expression in the ileum of mice at 10 weeks of age (Fig. 7b) ; this might have contributed to the lower production of IL-17 and IL-22 by MAIT cells at disease onset than by MAIT cells from younger mice. That defect in cytokine production was also associated with significantly increased gut permeability (Fig. 7c) .
To investigate whether the gut microbiota could directly affect the function of MAIT cells, we used an in vitro bioassay to measure the effect of bacterial agonist ligands in intestinal contents at various stages of disease development. Much like the MAIT ligand 5-OP-RU, intestinal contents activated purified MAIT cells in a dose-dependent manner (Fig. 7d,e) . This activation was MR1 specific, since it was inhibited by the addition of the antagonist ligand Ac-6-FP (Fig. 7d-f) . The activation of MAIT cells by the intestinal contents of young NOD mice (early stage), pre-diabetic NOD mice and diabetic NOD mice (onset of diabetes) did not reveal a significant modification in the concentration of MAIT-cell ligands (Fig. 7g) . These data suggested A r t i c l e s that the defective production of IL-17 and IL-22 by MAIT cells might have been due to lower production of IL-23 in diabetic mice, which in turn was associated with increased gut permeability.
MAIT cells control diabetes and intestinal homeostasis
To determine the role of MAIT cells in the pathogenesis of T1D, we generated Mr1 −/− NOD mice, since MR1 is required for the thymic A r t i c l e s development of MAIT cells 17, 29 . We analyzed Mr1 −/− and Mr1 +/− NOD littermates in co-housed conditions to exclude the possible effect of different gut microbiota on the function of MAIT cells. As expected, Mr1 −/− NOD mice lacked MAIT cells, whereas there were no significant differences between Mr1 −/− NOD mice and their Mr1 +/− NOD littermates in the frequency of Foxp3 + regulatory T cells, invariant natural killer T cells or γδT cells in the spleen and PLNs (Fig. 8a and Supplementary Fig. 6 ). However, Mr1 −/− NOD mice developed accelerated diabetes compared with that of their Mr1 +/− NOD littermates (Fig. 8b) , indicative of a protective role for MAIT cells in T1D. We also observed a protective role for MAIT cells directed against T1D in studies in which we treated mice with multiple low doses of streptozotocin, which is commonly used to induce T1D in C57BL/6 mice 39 . For these studies, we used Mr1 −/− of the Mus musculus castaneus ('CAST') subspecies that have the greatest frequency of MAIT cells (B6-MAIT CAST ). These mice were more susceptible to streptozotocin-induced T1D development than were their Mr1 +/− B6-MAIT CAST littermates (Supplementary Fig. 7 ). In confirmation of the incidence results obtained for NOD mice (Fig. 8b) , there was a greater frequency of anti-islet CD8 + T cells specific for the autoantigen IGRP ('islet-specific glucose-6-phosphatase-catalytic-subunitrelated protein') 40 and IFN-γ + anti-IGRP CD8 + T cells in the PLNs and pancreatic islets, respectively, of Mr1 −/− NOD mice than in those of their Mr1 +/− NOD littermates (Fig. 8c,d ). Since PLN dendritic cells (DCs) have a key role in the priming of anti-islet T cells 41, 42 , we analyzed DC phenotypes in both lines of NOD mice. In support of the finding of an enhanced anti-islet T cell response, the frequency of CD11c + CD11b + CD103 + DCs [43] [44] [45] was greater in the PLNs of Mr1 −/− NOD mice than in those of their Mr1 +/− NOD littermates, and those DCs had higher expression of MHC class II molecules and the costimulatory molecule CD86 (Fig. 8e) , reflective of their more activated status. Since the integrity of the gut mucosa controls the activation of immune cells 39 and MAIT cells are abundant and activated in this tissue, we explored the gut mucosa of Mr1 −/− NOD mice. The lack of MAIT cells in those mice resulted in significantly greater intestinal permeability than that of their Mr1 +/− NOD littermates, as evaluated by the level of fluorescein isothiocyanate (FITC)-dextran in the blood after oral gavage (Fig. 8f) . Reduced expression of mRNA encoding occludin and mucin2 confirmed the defective function of gut epithelial cells, and histological analysis showed an abnormal accumulation of mucus in the goblet cells of Mr1 −/− NOD mice (Fig. 8g,h ). Those abnormalities were associated with increased infiltration of lymphoid cells into the lamina propria (Fig. 8i) . As for the role of MAIT cells in the control of gut integrity and DC priming in the PLNs, significantly more bacterial 16S DNA was detected in the PLNs of Mr1 −/− NOD mice than in those of their Mr1 +/− NOD littermates (Fig. 8j) . These data suggested a link among MAIT cells, the gut mucosa and the enhanced anti-islet T cell responses (Supplementary Fig. 8 ).
DISCUSSION
This study has revealed alterations in the MAIT cells of patients with T1D as well as in those of NOD mice. The frequency of MAIT cells was lower in the peripheral blood of patients than in that of healthy children. Such a decreased frequency might reflect their migration from the blood to inflamed tissues, as has been described in other inflammatory and autoimmune diseases [22] [23] [24] 27, [46] [47] [48] and as supported by their increased frequency and migration into the pancreas of NOD mice during T1D development. The lower frequency of blood MAIT cells might have also resulted from their sustained activation, leading to cell exhaustion, as indicated by their expression of BCL-2, CD25 and PD-1 and by their defective in vitro response to antigen-specific stimulation, in contrast to their increased production of cytokines and GzB after stimulation with PMA and ionomycin. Of note, the MAIT-cell defect in T1D not only might be a consequence of diabetes development but also might reflect intrinsic differences between NOD mice and other strains (such as B6). Indeed, MAIT cells were less frequent and had a less-mature phenotype (on the basis of CD44 expression) in NOD mice than in C57BL/6 mice. Our study of NOD mice indicated that the phenotype and function of MAIT cells differed according to their tissue localization. The heterogeneity of MAIT cells observed in mice might explain the mosaicism of MAIT-cell populations detected in the blood of control donors and patients with T1D. It would be interesting to further investigate the recirculation of MAIT cells between peripheral tissues and the blood. However, the study of blood MAIT cells in NOD mice was not performed due to their extremely low frequency.
The analysis of peripheral tissues from NOD mice highlighted the role of MAIT cells in two tissues: the pancreas and the gut mucosa. In the pancreas, not only was the frequency of MAIT cells increased with diabetes development, but their production of GzB and IFN-γ, which might participate to the destruction of β-cells 4,5 , was as well. Most interestingly, in the youngest children with recent-onset T1D, which is usually associated with more-aggressive disease 31, 32 , circulating MAIT cells from the youngest children with recent-onset T1D had higher expression GzB than that of MAIT cells from older children with recent-onset T1D. This parameter had the strongest correlation with clinical characteristics, age at diagnosis and frequency of HbA1c. Of note, increased production of GzB was not observed in other T cell populations. Moreover, co-culture experiments showed that MAIT cells were able to directly kill a human β-cell line.
In contrast to their role in the pancreas, in the gut mucosa, MAIT cells might have a protective role through their production of IL-17A and IL-22, two key cytokines in intestinal homeostasis 37, 38, 49, 50 . The presence of gut alterations as T1D progressed in NOD mice emphasized the importance of MAIT cells in maintaining homeostasis of the gut mucosa. Moreover, the lack of MAIT cells in Mr1 −/− NOD mice was associated with a loss of gut integrity, as shown by the FITC-dextran assay, as well as decreased expression of tight-junction proteins and abnormal distribution of mucus. The absence of MAIT cells in NOD mice favored gut leakiness that was associated with the translocation of bacteria components, such as 16S bacterial DNA, from the gut to peripheral tissues. The presence of bacterial DNA might promote the development of T1D through the stimulation of DCs via nucleic-acid sensors and, consequently, increased activation of anti-islet pathogenic T cell responses in the PLNs. Together our data supported a model in which deficiency in MAIT cells aggravates alterations to the gut mucosa and thereby promotes the development of T1D. These data are reminiscent of published reports showing a critical link between the gut mucosa and the development of inflammatory and autoimmune diseases, including T1D 39 . MAIT cells might act as a sensor of environmental changes by responding to alterations in the gut mucosa by modulating the host immune system. Their abundance and activation status (production of CD69 and cytokines) in the gut might explain the prominent regulatory role of MAIT cells in the intestinal mucosa of NOD mice. Overall, these data lead us to propose that MAIT cells are at the crossroads of the gut mucosa, inflammation and T1D.
Interestingly, alterations in MAIT cells in both patients and mice have been detected before the onset of diabetes, which indicates that MAIT cell might represent a new biomarker for the development of T1D. It would be interesting to further investigate in T1D the link between the function of MAIT cells and the gut microbiota. Our data A r t i c l e s suggesting a protective role for MAIT cells in NOD mice at the level of the gut mucosa might pave the way for the development of new therapeutic strategies based on their local triggering in this tissue at an early phase of disease development.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Human samples. Peripheral blood samples were obtained from control children, from children with T1D admitted to the Pediatric Endocrinology department of Necker hospital, Paris, France at the onset of T1D (i.e., within 10 d of the first insulin injection) or from children with established disease. All control children were children who presented at the hospital for growth retardation, short stature or precocious puberty. None had any other medical conditions or history of autoimmune disease. Patients with growth retardation or short stature were admitted for a growth-hormone-stimulation test. All were previously screened for celiac disease or autoimmune thyroiditis (which can be an etiology of short stature). This screening was negative for all patients. All of these control children were diagnosed with idiopathic growth-hormone deficiency or idiopathic short stature. Patients with precocious puberty did not have any history of autoimmune disease. They were admitted for a gonadotropin-releasing-hormone-stimulation test and were diagnosed with idiopathic central precocious puberty. All control patients were screened and found to be negative for T1D-related antibodies. Exclusionary clinical parameters included infection during the admission and other associated autoimmune diseases. The Ethics Committee (Comité de protection des personnes (CPP) Ile-de-France) approved the clinical investigations, and written informed consent was obtained from all the parents. For the Milan cohort, peripheral blood was obtained from healthy control subjects and from patients at the onset of T1D (i.e., within 10 d of the first insulin injection). The study was approved by the San Raffaele Hospital Ethic Committee (protocol: DRI-003). At-risk subjects were enrolled in the Type 1 Diabetes TrialNet Pathway to Prevention Trial (TN01 trial, former TrialNet Natural History Study) 51, 52 . The overall objective of this study is to perform baseline and repeated assessments over time of the immunological and metabolic status of people who are at risk for T1D (first-or second-degree relatives of patients with T1D). Non diabetic children from Milan cohort were enrolled in the Department of Orthopedic Pediatric Surgery and had elective orthopedic surgery with no concomitant disease. The study was approved by the San Raffaele Hospital Ethics Committee (protocol: NHPROTOCOL32803 TN01). Our local study was approved by the TrialNet Ancillary Studies Subcommittee. All subjects included in this study provided informed consent before blood donation.
Mice. Mr1 +/− NOD mice were generated by the backcrossing (>15 times) of Mr1 −/− C57BL/6J mice 17 onto the NOD background; 17 insulin-dependent diabetes loci associated with susceptibility to T1D have been checked on all chromosomes. Mr1 −/− NOD mice were generated by intercrossing of Mr1 +/− NOD mice, and the analyses were performed with Mr1 −/− and Mr1 +/− NOD littermates kept in co-housed cages. The transgenic RORγt-GFP NOD mouse was generated by microinjection of a RORγt-GFP BAC construct 53 into NOD embryos. Mr1 −/− and Mr1 +/− B6-MAIT CAST mice were provided by O.L. 35 . All mice were bred under specific pathogen-free conditions, and the study was performed on female mice, except the steptozotocin experiments. NOD mice were tested weekly (daily in steptozotocin experiments) and were considered diabetic after two consecutive positive urine glucose tests (DIABUR-TEST 5000, Roche), confirmed by glycemia of >200 mg/dl (ACCU-CHEK, Roche). This study was approved by the ethics committee on animal experimentation CEEA 34 (APAFIS N°2015102016444419).
Cell preparations.
Human peripheral blood mononucleated cells (PBMCs) from patients at Necker Hospital were isolated from fresh blood samples by Ficoll-Paque (Leucosep), or samples from San Raffaele hospital were defrosted in RPMI medium with 10% FCS (Fetal Cow Serum). Mouse cells were prepared from various tissues as described below. For isolation of pancreatic islets, mice were killed and the pancreas was perfused with 3 ml of a collagenase P solution (0.8 mg/ml, Roche); it was then isolated and set free from surrounding tissues and lymph nodes. Digestion of the pancreas was performed at 37 °C for 10 min and was stopped by the addition of a large volume of cold 5% FCS plus RPMI medium before extensive washes. Pancreatic islets were then purified on a Ficoll discontinuous gradient. For immunofluorescence analysis, islets were dissociated with a non-enzymatic cell-dissociation solution (Sigma). For isolation of intestine cells, a Miltenyi Lamina Propria Dissociation Kit for mouse was used to prepare epithelial and lamina propria cells. Mice were killed and the intestine was removed from mice. The intestine was cleared of feces, fat tissue and Peyer's patches with HBSS without Ca 2+ or Mg 2+ , containing 10 mM HEPES. After passage through a 100-µm filter, the cell suspension was subjected to a Percoll density gradient (GE Healthcare) of 40% and 80%, and the interface between the layers containing lamina propria lymphocytes was collected and suspended in PBS containing 2% FCS and 0.1% sodium azide. For the preparation of mouse DCs from lymph nodes and spleen, mice were killed and their organs were cut in small pieces and then digested at 37 °C for 30 min with 2 ml of collagenase D (1.0 mg/ml, Roche) solution. Digestion was stopped by the addition of a large volume of cold 5% FCS plus RPMI medium, and cells were washed and filtered on cell strainer (40 µm, BD Falcon) before staining.
Flow cytometry and antibodies. Cells were stained in PBS containing 5% FCS and 0.1% sodium azide. For human PBMCs, the following antibodies were used: monoclonal antibodies (mAbs) to CD3 (OKT3), CD4 (OKT4), V α 7.2 (3C10), CD161 (HP-3G10), CCR6 (G034E3), CD56 (HCD56), CD69 (FN50), BCL-2 (100), IFN-γ (4S B3), IL-17A (BL168), TNF-α (MAb11) and MR1 (26.5), all from BioLegend; mAbs to CD8 (SK1), PD1 (MIH4), CD25 (M-A251), IL-4 (8D4-8) and granzyme B (GB11), and anti-CD107a (HYA3), all from BD Biosciences; mAbs to CD3 (REA) and CD161 (REA), both from Miltenyi; and mAb to CD4 (RPA-T4), from eBiosciences. According to the number of PBMCs obtained from each patient, surface staining was always performed, and when possible due to the number of PBMCs, intracytoplasmic staining of cytokines and GzB was analyzed after stimulation with PMA and ionomycin, and then PBMC expression of BCL-2 was analyzed by intracytoplasmic staining (without stimulation). Data acquisition was performed with a BD Biosciences LSR-Fortessa cytometer or FACSAria III cytometer for cells from patients from Necker hospital and with a Beckman Coulter Gallios for cells from patients from San Raffaele hospital.
Staining of mouse cells was performed with the following antibodies: mAbs to TCRβ (H57), TCR-γδ (GL3), CD45 (30F11), CD8α (53−6.7), CD103 (M290), CD44 (IM7), I-Ak (10-3.6CD45), CD86 (GL1), IL-17A (TC11-18H10), TNF (MP6-XT22) and IFN-γ (XMG1.2), all from BD Biosciences; mAbs to CD19 (6D5), CD4 (GK1.5), CD11b (M1/70), PLZF (9E12), T-bet (4B10), CD25(PC61), CD69 (HI-2F3), IL-22 (5164), CD103 (3E12) and CXCR3 (SA011F11), all from BioLegend; and mAbs to CD11c (N418), CD170 (1RNM44N), F4/80 (BM8), RORγt (B2D) and FOXP3 (FJK-16s), all from eBioscience. The CD1d-α-galactosylceramide tetramer was prepared by the A.L. laboratory and was coupled to streptavidin-BV421 (BioLegend). T cells reactive to the NRP-V7 tetramer (T cell reactive to IGRP (amino acids 206-214) (KYNKANVFL)) and the TUM tetramer (TUM (KYQAVTTTL) were provided by the National Institutes of Health tetramer core facility. Biotinylated mouse MR1 tetramers loaded with the active ligand (5-OP-RU) were used to specifically identify MAIT cells, and biotinylated MR1 tetramers loaded with the non-activating ligand acetyl-6-formyl-pterin (Ac-6-FP) were used as a negative control. MR1 tetramers were coupled to streptavidin-PE (BD Biosciences) or streptavidin-BV421 (BioLegend), and cells were stained with tetramers for 45 min at room temperature before surface staining with mAbs (identified above). Data acquisition was performed using a BD Biosciences LSRFortessa or FACSAria III cytometer, and cell were sorted using a FACSAria III cytometer (purity >98%). Flow cytometry was performed with FlowJo analysis software V10.1 (Tree Star), and Spice software V5.3 was used for studying the multi-parameter combination of cellular staining. been performed on the human results when we compared flow cytometry data from the three groups (children with recent-onset T1D, children with established T1D and control children). Corrections have well been applied after use of the signed-rank Wilcoxon test with an adjustment of the P value with the Holm method to take into account the fact that multiple testing had been performed. A factorial discriminant analysis was performed using the XLSTAT 2016 Software. A logistic regression model was fitted with PROC CANDISC software (SAS version p.3), then a backward elimination procedure was applied. Prognostic validity of the model was evaluated by analysis of the receiver operating characteristic curve and was measured using the area under the curve (AUC). Statistical analyses were performed using GraphPad Prism software version 5.00.288 and R software version 3.2.3. For mouse studies, statistical analysis was performed with Prism software (Graph Pad) using nonparametric tests two-tailed Mann-Whitney or Student's t-test, as appropriate. Diabetes incidence was plotted according to the Kaplan-Meier method, and statistically significant differences between groups were analyzed using the Gehan-Breslow-Wilcoxon test or the log-rank test. The following P values were considered statistically significant: *P < 0.05, **P < 0.01 and ***P < 0.001.
A Life Sciences Reporting Summary for this paper is available. 
Data exclusions
Describe any data exclusions. no
Replication
Describe whether the experimental findings were reliably reproduced.
Yes data were reproduced, in patient two cohorts were analyzed , from Paris and Milano. For mouse studies, at least three independent experiments were performed and the incidence of diabetes was performed with 62 animals.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
MR1 +/-and MR1 -/-mice were randomized in the cages at weaning after the genotyping performed at two weeks of age.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All experiments in humans and mice were performed blinded.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Human peripheral blood mono-nucleated cells (PBMC) of patients from Necker Hospital were isolated from fresh blood samples by Ficoll-Paque (Leucosep) or PBMC samples from San Raffaele hospital were defrosted in RPMI with 10% FCS (Fetal Cow Serum).
Mouse cell preparations.
For Pancreatic islets isolation, mice were sacrificed and pancreas was perfused with 3 mL of a collagenase P solution (0.8 mg/mL, Roche), which was then isolated and set free from surrounding tissues and lymph nodes. Digestion of the pancreas was performed at 37°C for 10 min and was stopped by adding large volume of cold 5% FCS RPMI before extensive washes. Pancreatic islets were then purified on a Ficoll discontinuous gradient. For immunofluorescence analysis, islets were dissociated with a non-enzymatic cell-dissociation solution (Sigma).
For Intestine cell isolation, Miltenyi Lamina Propria Dissociation Kit for mouse was used to prepare epithelial and lamina propria cells. Mice were sacrificed and intestine was removed from mice. Intestine was cleared of feces, fat tissue and Peyer's patches with HBSS without Ca2+ and Mg2+ containing 10 mM HEPES solution. After passage through 100 μm filter, the cell suspension was subjected to Percoll (GE Healthcare) density gradient of 40% and 80% and the interface between the layers containing lamina propria lymphocytes were collected and suspended in PBS containing 2% FCS and 0.1% sodium azide.
For the preparation of mouse dendritic cells from lymph nodes and spleen, mice were sacrificed and organ were cut in small pieces and then digested at 37°C for 30 min with 2 mL of collagenase D (1.0 mg/mL, Roche) solution. Digestion was stopped by adding a large volume of cold 5% FCS RPMI, and cells were washed and filtered on cell strainer (40 μm, BD Falcon) before staining.
